(Health-NewsWire.Net, July 19, 2017 ) RNAi Drug Delivery means sending artificial drugs into our body to inhibit gene expression and preventing cancerous cells to increase. RNAi drugs are used to cure various chronic diseases. Right now, Research is being carried out to find right genes to cure cancer. This market has high potential in the near future.
To view full report: http://www.marketdataforecast.com/market-reports/middle-east-and-africa-rnai-drug-delivery-market-1981/
Few factors like increasing incidence of chronic diseases like cancer and cardiovascular diseases, and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also fueled the growth in Middle East and Africa RNA Drug Delivery Market. But, High investments and stringent Regulations are some of the major restraints to this market. Targeted Delivery of RNAi Drugs is the key challenge faced by the market. Availability of advanced technology here compared to developed regions is low which is restraining the market’s growth.
Middle East and Africa RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into pulmonary drug delivery technology, aptamer drug delivery technology, nucleic acid drug delivery technology and nanoparticle drug delivery technology. Based on Therapeutic Application, the market is further segmented into cardiology, metabolic disorders, oncology, ophthalmology, infectious diseases and neurology.
Free sample of the report is available at: http://www.marketdataforecast.com/market-reports/middle-east-and-africa-rnai-drug-delivery-market-1981/request-sample
Based on Geography, this market is further segmented into Middle East and Africa. CAGR is low here compared to other regions because of lack of advanced research facilities and major nations around here.
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail: abhishek@marketdataforecast.com Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/ View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com
|